peripheral T-cell lymphoma
Haematology · 2015–2017
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pralatrexate Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following first-line chemotherapy. | Jul 2017 | Not recommended | input received Rare Cancer Australia |
| pralatrexate Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adult patients who have progressed after at least one prior therapy. | Nov 2017 | Recommended with restriction | 1 individuals |
| romidepsin Relapsed or chemotherapy refractory peripheral T-cell lymphoma (PTCL) in patients who have received and failed prior systemic therapy and are not candidates… | Nov 2016 | Not recommended | 2 individuals Rare Cancers Australia |
| pralatrexate Treatment of relapsed or refractory peripheral T-cell lymphoma in adult patients who have progressed after at least one prior therapy. | Nov 2015 | Not recommended | none received |
Who spoke
Rare Cancer Australia · Rare Cancers Australia
What the PBS pays
$3M in government benefit over 2024–25, across 1,006 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| pralatrexate | $3.2M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.